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INTRODUCTION 
 
Hyperuricemia was first discovered by Alfred Baring Garrod (1), who 
showed that in patients with gout, there was a high level of uric acid 
content. Some researchers consider hyperuricemia as a positive factor, 
especially due to the observation that uric acid can function as an 
antioxidant that can block superoxide, peroxynitrite, and iron-catalyzed 
oxidation reactions. 
 
However, recent studies in the western world have shown 
asymptomatic hyperuricemia to be associated with poor outcome in those 
with cardiovascular disease and those with renal insufficiency (2). Uric acid 
levels correlate with prehypertension, hypertension and with other 
components of metabolic syndrome. 
 
Hyperuricemia in prehypertension & hypertension may be causal or a 
consequence. Hyperuricemia is found to stimulate smooth muscles in vessel 
wall and induce endothelial dysfunction which plays a critical role in 
pathogenesis of hypertension. Hypertension can, in turn, induce renal 
dysfunction resulting in reduction in GFR and renal urate excretion. Though 
studies show elevated uric acid levels in both the Prehypertensive and 
hypertensive groups, studies analysing the correlation of uric acid levels 
among the Prehypertensive and hypertensive groups are few. Also a 
quantitative correlation may act as a marker of severity of endothelial 
dysfunction in these subjects (40). Hence studies are required to quantitate the 
levels of uric acid among both Prehypertensive and hypertensive groups 
(with stage I & II as sub groups) and see if higher levels of uric acid are 
found as BP levels become higher. 
 
Though ample amount of literature and studies supporting the causal 
role of hyperuricemia in hypertension is available, studies in this regard are 
lacking in the Indian scenario. The present study is undertaken to generate 
credible information and evidence concerning this topic. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
HYPERTENSION 
Hypertension is one of the most commonly encountered diseases in 
the outpatient setting with an estimated prevalence of 30 %. Starting from as 
low as 115/75 mmHg, the mortality from cardiovascular disease can 
increase by almost upto 200% for every rise of BP by 20/10 mmHg. This 
truly places a tremendous burden on the health care sector and hence the 
perennial interest in Hypertension- the various aetiologies, its 
pathophysiology and various drug targets to control blood pressure. The 
problem with this disease is that it many a times remains silently hidden 
inside the unaware patient and shows its ugly head as one of its severe 
complications usually as a result of end organ damage. Approximately one- 
third of adults are unaware of their hypertensive status and almost 66% fall 
short of their target blood pressure (11). 
 
HISTORY: 
The understanding of hypertension has evolved since the time of 
William Harvey (1578–1657), who was the first to describe the blood 
circulation in his famous book "De motu cordis". Stephen Hales, an English 
clergyman, a botanist and a part time chemist, first made the published 
measurement of blood pressure in 1733, by sacrificing his mare and 
cannulising its arteries. Thomas Young in 1808 and Richard Bright in 1836 
were the first to describe Hypertension as a disease. However, what truly 
revolutionized the diagnosis of hypertension was the invention of 
sphygmomanometer (sphygmos, pulse; manos, scanty; metron, measure) by 
Scipione Riva-Rocci in 1896. This eased the procedure of evaluation of BP 
in outpatient settings. In 1905, Nikolai Korotkoff  identified that there was 
disappearance of sounds on deflating the cuff from a higher pressure and 
marked the systolic pressure using a stethoscope. Hypertension was often 
classified into "malignant" and "benign" in the early 20th century. However 
it was increasingly recognised in the 1950s that the latter was not innocuous 
as it sounds. Over the next few years, increasing evidence accumulated from 
various studies, that even lower grades of hypertension increased death and 
cardiovascular disease, and that these risks increased in a predictable 
fashion with rising blood pressure across the spectrum of blood pressures. It 
is interesting that historically the treatment primarily consisted in reducing 
the quantity of blood either by bloodletting or by the usage of leeches to 
suck out blood (3-6). 
 
DEFINITION: 
For epidemiologic and practical reasons, hypertension is currently 
defined as a systolic pressure of ≥140 mm Hg and/or a diastolic blood 
pressure of ≥90 mm Hg. This is based on the mean of two or more blood 
pressure measurements in a person in two or more visits ideally a month 
apart. This value is reduced to 130 and 80 respectively for patients with DM 
and CKD (8). However Blood pressure is a continuous variable with a 
correspondingly variable cardiovascular risk, and hence using definitive 
numbers is purely on convenience and is arbitrary. It would probably be 
better to describe systemic hypertension as a progressive cardiovascular 
syndrome characterized by the presence of elevated BP to a level that places 
a person at increased risk for vital organ injury secondary to vascular 
pathology. 
 
CLASSIFICATION: 
The “Joint National Committee (JNC) on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure” has, over years, 
studied patterns of hypertension and given the classification and guidelines 
in the management of hypertension. The latest is the seventh report of JNC 
(7) and the classification of hypertensive groups holds two primary changes 
over their sixth; one is the introduction of a new sub group called pre- 
hypertension, as it was becoming clearer that risk for cardiovascular disease 
started at much lower values that was previously considered. The second is 
the merger of what was previously considered as stage 2 & 3 into a single 
stage, as management of either one is similar. 
 
 The present classification reads thus: 
 
 
 Some other terms of significant interest are: 
Pseudo hypertension refers to the falsely elevated blood pressure measured 
on sphygmomanometer due to the stiffening of the vessel wall. This can be 
identified by Osler’s manoeuvre, where the artery remains palpable despite 
an absent pulse, on inflation of cuff. 
 
 Malignant hypertension is one where the elevated blood pressure is 
associated with end organ damage, as in rapid deterioration of renal 
function, retinal haemorrhages or optic nerve involvement, left ventricular 
failure, myocardial ischemia, or cerebrovascular accident. These changes 
are independent of the blood pressure value, but usually the measured blood 
pressure is above 180/110 mm Hg. 
 
 BLOOD PRESSURE MEASURING TECHNIQUE is of vital 
importance to accurately identify those at risk, and ones requiring treatment. 
Ideally the patient is to be seated comfortably with arms supported at the 
level of heart. It is advisable that the patient avoids caffeine, exercise and 
smoking at least 30 minutes before the measurement. An appropriate cuff 
with bladder encircling atleast 80% of arm circumference is to be used. The 
cuff is inflated 20 to 30 mm Hg beyond the level where radial pulse is not 
felt and then deflated at the rate of 2 mm Hg/ sec. Appearance of Korotkoff 
sound 1 & disappearance of sound 5 are taken as SBP and DBP (11). 
Nowadays Ambulatory Blood Pressure Monitoring (ABPM) is increasingly 
being used, especially in cases of white coat hypertension, borderline 
hypertension, resistant hypertension, and in those on antihypertensive drugs 
with symptoms suggestive of hypotension. 
 
EPIDEMIOLOGY: 
Worldwide prevalence for hypertension is found to be as high as 
1.1billion individuals, and every year as many as 7.1 million people die due 
to various complications of hypertension. The World Health Organization 
reports that more than 60% of cerebrovascular disease and almost 50% of 
ischemic heart disease are due to suboptimal BP (115 mm Hg SBP) which 
also happens to be the most common attributable risk for death across the 
world. 
 
In India, 57% of all stroke deaths and 24% of CAHD deaths can be 
attributed to hypertension (9).  There has been a steady increase in the 
prevalence of hypertension in rural India over time. Recent studies have 
shown a much higher prevalence of hypertension among urban adults:  
 
 MEN WOMEN 
JAIPUR(2002) 36 37 
TRIVANDRUM(2000) 36 31 
MUMBAI(1995) 44 45 
CHENNAI(2001) 14 14 
 
Pooling the data, it seems hypertension is present in nearly a quarter 
of the urban and a tenth of rural Indians, which translates to an approx. 31.5 
million hypertensive people in rural and 34 million in urban localities. 70% 
of them would be Stage I hypertension. 
 
GENETIC CONSIDERATIONS: 
Although a rare Mendelian form of hypertension is identified in a 
few subgroups, majority of population have a multifactorial aetiopathology 
for development of hypertension which includes familial, environmental, 
and dietary factors among others. 
 
Some of the genes that have been implicated, as in studies using rats 
and human genome (11) include: 
• Genes that encode for components of the RAS system  
• Angiotensinogen and ACE polymorphism 
• The α-Adducin gene that causes increased sodium reabsorption in 
tubules. These three genetic components are involved in influence of 
dietary sodium. Others include genes for β2 adrenoceptors, AT1 
receptor and aldosterone synthase. 
 
AETIOLOGICAL CLASSIFICATION: 
This could be either (12) 
A. Essential Hypertension 
B. Secondary Hypertension: 
• Kidney disease 
• Endocrine causes 
• Cardiovascular states 
• Neurological disorders 
• Rare Mendelian forms of HT (glucocorticoid remediable 
Hypertension, 17α- and 11β hydroxylase deficiency, Liddle’s 
syndrome, PCKD, Pheochromocytoma etc.) 
 
PATHOPHYSIOLOGY OF HYPERTENSION: 
The multiple mechanisms involved in hypertension signify an 
abnormality in the normal regulation of blood pressure. Blood pressure is 
primarily a function of cardiac output and peripheral vascular resistance (12). 
Indeed, it is a complex trait that is determined how various factors- dietary, 
environmental, demographic, genetic interact to influence these two factors. 
Cardiac output depends on the total blood volume which is in turn 
influenced by total body sodium. Total peripheral vascular resistance is a 
function at the level of arterioles and is under the influence of both 
humoral& neural factors-vasoconstrictors (ATI, Endothelin, 
catecholamine), vasodilators (NO, Kinins, PG). Other factors include pH, 
adrenergic system and hypoxia. 
 
 
 
The Renal regulation of blood pressure occurs: 
 Via the RAAS (Renin Angiotensin Aldosterone System), the kidney 
modulates the sodium homeostasis and peripheral vascular 
resistance. 
 The kidney also produces various vasodilators like NO and 
prostaglandins which counterbalances the effects of angiotensin. 
 With fall in ECF, the GFR falls, and sodium reabsorption occurs in 
proximal tubules. 
 
As previously mentioned, there is an inverse relationship between 
renal perfusion pressure and proximal sodium reabsorption. If this were to 
be true in all cases, this pressure natriuresis should cause profound volume 
depletion in the hypertensive patients which doesn’t happen in most of the 
patients. This suggests that in all hypertensive patients, there is a shift in 
the pressure natriuresis curve in such a manner that a higher perfusion 
pressure is needed to achieve the required level of natriuresis. This was 
studied by Guyton et al who postulated that the shift in the pressure 
natriuresis curve is fundamental pathophysiological abnormality that is 
responsible for all forms of hypertension (13).   
 
 
 
 
According to him, “the most important mechanism in determining 
the long term control of blood pressure is the renal fluid- volume feedback 
mechanism” i.e. kidney regulates arterial pressure by altering the excretion 
of salt and water through kidney, thereby maintaining the circulatory 
volume and cardiac output. Any change in BP leads to an alteration of 
sodium and water excretion. When this feedback mechanism gets deranged, 
hypertension results and is, in essence, the fundamental mechanism 
governing long term hypertensive states due to any cause. 
 
In all hypertensive states, an intrinsic natriuretic abnormality exists, 
so that sodium cannot be excreted at normal BP and hence the hypertension 
essentially becomes necessary to induce pressure natriuresis. Thus 
hypertension becomes a protective phenomenon as it induces kidney to 
undergo diuresis, thereby restoring normal salt and water homeostasis. This 
also explains why patients with salt- sensitive hypertension (where there is 
an underlying problem in sodium excretion) usually doesn’t manifest with 
fluid overload state. 
 
Renin-Angiotensin-Aldosterone 
Renin, an aspartyl protease is synthesized from its precursor, 
prorenin, in the renal afferent renal arteriole. Prorenin may be secreted 
directly into the circulation or may be activated within secretory cells and 
released as active renin. The primary stimuli for renin secretion are:  
1. Decreased sodium chloride concentration sensed at macula densa, a 
part of Juxtra Glomerular Apparatus (14), 
2. Decreased pressure sensed in renal afferent arteriole (baroreceptor 
mechanism), and 
3. Stimulation of β1 adrenoceptors. 
 
Conversely, renin secretion increases due to either ACE or 
angiotensin II receptors blockade. Active renin cleaves Angiotensinogen 
into Angiotensin I which on further metabolism in liver, is converted to 
Angiotensin II by Angiotensin- Converting Enzyme (ACE).  
 
Renin-secreting tumours are one of the examples of renin-dependent 
hypertension. These include benign hemangiopericytomas, Wilms' tumour 
& renin-producing carcinomas in lung, liver, pancreas, colon, and adrenals. 
Renovascular hypertension is another renin-dependent hypertension. Renal 
artery obstruction leads to decreased renal perfusion pressure, which in turn 
stimulates renin secretion. Over time, due to secondary renal damage, this 
may become less renin dependent. 
 
Angiotensin II is a potent vasopressor, the primary tropic factor for 
aldosterone secretion by the zona glomerulosa, and a growth factor for 
vascular smooth muscle cell and myocyte growth and contributes to 
modeling and repair. Excessive angiotensin II may accelerate 
atherosclerosis, cardiac hypertrophy, and renal failure and thus may be a 
target for therapy to prevent target organ damage. 
 
Aldosterone synthesis is dependent on AT II, potassium, and ACTH 
to a smaller extent. Aldosterone is a potent mineralocorticoid that causes an 
increase in reabsorption of sodium by amiloride-sensitive epithelial sodium 
channels (ENaC).  Its activation induces structural and functional alterations 
in the kidney, heart and blood vessels, causing nephrosclerosis, myocardial 
ischemia and vascular inflammation and remodeling. Animal models have 
shown that high circulating aldosterone levels can stimulate cardiac fibrosis 
and left ventricular hypertrophy, and that spironolactone (an aldosterone 
antagonist) prevents it.  
 
Autonomic Nervous System 
The ANS helps in maintaining cardiovascular homeostasis via 
volume, pressure, and chemoreceptor signals. Adrenergic reflexes modulate 
short term BP, and adrenergic function, along with hormonal factors, 
contributes to the long-term regulation. In the kidney, activation of α1-
adrenergic receptors increases renal tubular reabsorption of sodium. 
Activation of myocardial β1 receptors increases cardiac output by positive 
chronographic and inotropic action. β1 Receptor activation also stimulates 
renin synthesis. 
 
Several reflexes modulate blood pressure on very short term basis. 
One of them is the arterial baroreflex which is mediated by sensory nerve 
endings in the arch of aorta and carotid sinus. With increase in arterial 
pressure, these receptors are activated and the net effect is a reduction in 
sympathetic outflow, causing hypotension and bradycardia.  Sympathetic 
outflow is found to be higher in hypertensive than in normotensive 
individuals. It plays a role in obesity-related hypertension and Obstructive 
sleep apnoea syndrome. Pheochromocytoma is the most explicit example of 
hypertension secondary to increased catecholamine production. 
 
Vascular Mechanisms 
Vascular radius and compliance of resistance arteries are important 
determinants of arterial pressure. Small reduction in lumen size can 
significantly increase resistance. Hypertensive patients have stiffer arteries, 
and hence patients with arteriosclerosis usually have high SBP and wide 
pulse pressures due to decreased vascular compliance. Recent evidence 
suggests that arterial stiffness has independent predictive value in cardiac 
events. 
 
 
Effects of Hypertension on organ systems 
(11) 
Hypertension is an independent predisposing factor for CAHD, CCF, 
peripheral arterial disease (PAD) and renal disease. 
 
CARDIOVASCULAR SYSTEM 
Hypertensive heart disease is the commonest cause of death in this 
group. Structural and functional adaptations of vascular system lead to 
LVH, CHF,CAHD and cardiac arrhythmias. Left ventricular hypertrophy 
increases the risk for CHD, CCF, stroke, and sudden death. Aggressive 
control of hypertension can partly reverse LVH and reduce cardiovascular 
risk. 
 
CCF may be either systolic dysfunction, diastolic dysfunction, or 
both. Diastolic dysfunction is seen often in this subgroup. Patients with 
diastolic heart failure have a normal EF which is a measure of systolic 
function. Cardiac catheterization is used to assess diastolic function. Other 
non-invasive methods, includes echocardiography and radionuclide 
angiography. 
 
CEREBROVASCULAR SYSTEM 
Hypertension is the strongest risk factor for cerebrovascular accident 
(CVA). Lack of proper management of hypertension increases the incidence 
of both thromboembolic and haemorrhagic strokes. 
 
Hypertension also is associated with earlier onset of dementia in 
elderly. This may be due either to large vessel ischemia or Lacunar Infarcts. 
Whether antihypertensive therapy can retard the progress of the cognitive 
dysfunction requires further studies. 
 
Autoregulation refers to the maintenance of cerebral blood flow over 
a wide pressure range (mean arterial pressure of 50–150 mmHg). In patients 
with malignant hypertension, failure of autoregulation of cerebral blood 
flow leads to vasodilation and hyperperfusion, and in turn, encephalopathy. 
Untreated, this can progress to stupor, coma, seizures, and death. Other 
neurologic syndromes that may be associated with hypertension are, space 
occupying lesions, benign intracranial hypertension and uremic 
encephalopathy. 
 
PERIPHERAL ARTERIES 
Blood vessels are a target organ for atherosclerotic disease due to 
hypertension. Hypertension with PAD is a marker for future CVD. 
Intermittent claudication is the classic symptom of PAD. The ankle-brachial 
index (ABI) is a useful for evaluating PAD and is defined as the ratio of 
noninvasively assessed ankle to brachial SBP. An ABI <0.90 is considered 
diagnostic of PAD. 
 
KIDNEY 
The kidney has a causal and effect relationship in hypertension. 
Primary renal disorders are the commonest cause of secondary 
hypertension. As analysed in the pathophysiology, various mechanisms play 
a role in kidney-related hypertension. This includes 
• A dysfunction in sodium excretion, 
• Excessive renin secretion, and 
• Over activity of sympathetic nervous system.  
 
Conversely, hypertension is a major risk factor for kidney injury and 
End Stage Renal Disease. The increased risk is present throughout the range 
of blood pressure above optimal level. This appears related to SBP rather 
than to DBP. Proteinuria is a reliable marker of assessing the severity of 
CKD and predicts its progression. Patients with higher levels of proteinuria 
(>3 g/24 h) have a rapid rate of progression than do those with lower levels. 
Atherosclerotic, hypertension-related vascular lesion primarily affects pre 
glomerular arterioles leading to ischemic changes in the glomeruli and post 
glomerular capillaries. Glomerular hyperperfusion plays a role in glomerular 
injury. Similar to brain, loss of autoregulation of renal blood flow at the 
afferent arteriole occurs, resulting in transmission of high pressures to 
unprotected glomeruli with resultant hyperfiltration, and focal segmental 
glomerular sclerosis. There occurs a vicious cycle of renal injury and loss of 
nephron leading to more severe hypertension, glomerular hyperfiltration, 
and further renal damage. This can progress to glomerulosclerosis, and over 
a period of time, the renal tubules also become ischemic and atrophic.  
 
Macro albuminuria (an ACR >300 mg/g) or micro albuminuria (a 
urine ACR 30–300 mg/g) are early pointer of kidney injury and are also risk 
factors for disease progression and CVD. Serum uric acid is also found to be 
elevated in patients with hypertension, as well as in prehypertension and this 
study is done in this regard. 
 
URIC ACID 
Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen, 
and hydrogen with the formula C5H4N4O3 
(15). 
 
 
It is a by-product of purine metabolism and is formed by the action of 
xanthine oxidase. Exogenous purines also make up a considerable part of 
uric acid and this is absorbed in the intestines. In humans, the total uric acid 
content is about 1.2 g and it is excreted in the kidneys 
 
 
 
 
Uric acid is degraded in most mammals by urate oxidase or uricase, 
to allantoin, which is excreted in the urine. However, about  10 million 
years ago, loss of function mutations in genes coding for this enzymes 
occurred in humans. Hence, we have higher uric acid levels (> 2 mg/dL) 
than most mammals (18, 19). The wide range in serum uric acid (upto 12 
mg/dL) in  humans is determined by the  balance between consumption of 
urate rich diet (such as high protein diets, alcohol consumption, 
physiological and pathological states with high cell turnover, or defects in 
purine metabolism), and uric acid elimination by renal and extra renal routes. 
A reduction in glomerular GFR increases serum urate levels, though a 
compensatory increase in gastrointestinal excretion also occurs. Increased 
net tubular absorption also causes hyperuricemia (16). The low solubility of 
uric acid in water is responsible for the development of gout. 
 
Uric acid is a potent reducing substance and hence, a good 
antioxidant, which makes up almost 50% of the oxidizing capacity of serum. 
In human blood plasma, the reference range of uric acid is 3.5 mg/dL to 
7.4 mg/dL (214- 494 µmol/L) for men and 2.2-6.7 mg/dL for woman (137-
393 µmol/L) (17). Values above these are considered to be hyperuricemia. 
Hyperuricemia is not diagnosis per se, but is associated with a variety of 
medical conditions.  
 
PATHOPHYSIOLOGY 
Renal uric acid excretion 
(20)
: About 90% of the uric acid filtered through 
the glomeruli is reabsorbed. There is a four step renal handling of uric acid. 
 
Step1: 100% filtration at glomeruli 
Step 2: 98-100% pre secretory reabsorption at proximal convoluted tubule 
(PCT) by active transport 
Step 3: 50% secretion of reabsorbed urate at PCT 
Step 4: 40-50% post-secretory reabsorption  
 
Finally, around 5-10% uric acid is excreted through urine, as final net 
absorption is 90-95%.  
 
Urate secretion can be correlated with its concentration in serum 
because a minimal rise in the latter results in a substantial rise in the former.  
 
Increased uric acid levels in serum occur due to: 
• decreased excretion (under excretors),  
• increased production (over producers), or  
• Both mechanisms. 
 
Overproducer status is determined by total excretion over 
1000mg/day and under excretors, below 600mg/day on a normal purine diet. 
A single urine sample for uric acid/creatinine ratio is also diagnostic of 
overproducer when the value is more than 0.5(normal is <0.5). The causes 
are presented later in the discussion. 
 
Urate Transporters (20, 21):  
There are two main renal transporters of the organic acid 
transporter (OAT) family: 
• URAT 1 is highly specific and localized to the apical brush border 
of proximal tubular lumen. Probenecid and benzbromarone increase 
urate excretion by inhibiting URAT 1 and other OATs. 
 
• GLUT 9 exists in two isoforms, GLUT 9L and GLUT 9S, located at the 
proximal tubular epithelial cells. GLUT 9 is also a transporter for 
glucose and fructose and thus has a role in dietary influences of 
glucose and fructose on hyperuricemia and gout. GLUT 9 is also 
inhibited by uricosuric agents like probenecid and benzbromarone. 
 
Other transporters are:  
• UAT 1- associated with luminal secretion of urate 
• ABCG 2 
• NPT 1, NPT 4- Sodium-dependent phosphate co-transporter 
 
Endogenous regulators of urate transport are: 
• Insulin 
• Leptin 
• Adiponectin 
• Oestrogen 
• Uratin 
 
ASYMPTOMATIC HYPERURICEMIA 
EPIDEMIOLOGY: 
It is defined as a serum urate level greater than 6.8 mg/dl, a level at 
which MSU remains soluble in serum at 37˚C; beyond which there is super 
saturation of body fluids and a possibility of deposition in various tissues. 
This level has been rounded off to 7.0 mg/dl in men and 6 mg/dl in women. 
 Asymptomatic hyperuricemia is not equivalent to gout. It is 
common and found in about 5 to 8% of adult males (22). It is more common 
in Phillipinos and south East Asians. The prevalence rate of asymptomatic 
hyperuricemia in USA is estimated at 2.1-13.1%.The risk of gouty arthritis 
and Urolithiasis increases with duration and severity of hyperuricemia. 
Clinical gout develops in only about 12% of patients with urate levels 
between 7.0 and 7.9 mg/dl over a 14 year period. 
 
When serum uric acid level is greater than 9.0 mg/dl, the 
probability of progression to clinical gout is six times. 
 
Hyperuricemia is more common in men than women and the basal 
value increases with age. 
 
AETIOLOGY: 
The cause of hyperuricemia can be classified based on the 
pathophysiological mechanism underlying them i.e., uric acid under 
excretion, uric acid over production, and combined causes. 
 
UNDEREXCRETION: 
• Idiopathic 
• Familial juvenile gouty nephropathy: It is a rare condition which is 
characterized by gradually worsening kidney function. Renal biopsy 
shows glomerulosclerosis and tubulointerstitial pathology. 
• Renal Disorders: Disorders of Kidney function is one of the more 
common causes. In CKD, the uric acid level starts rising as the 
creatinine clearance≤ 20 mL/min, due to a decrease in urate clearance 
as retained organic acids compete for secretion. 
• Metabolic Syndrome (23, 24). 
• Drugs: These include diuretics, pyrazinamide, ethambutol, levodopa, 
aspirin, cyclosporine, nicotinate, and fluorinated anaesthetics. 
• Hypertension 
• Acidosis: Including lactic acidosis, DKA, alcoholic ketoacidosis, and 
starvation ketosis. This is due to the fact that these organic acids 
formed in aforementioned conditions compete with urate for tubular 
secretion. 
• Preeclampsia and eclampsia: Hyperuricemia is a constant finding and 
used in diagnosis. 
• Hyperparathyroidism 
• Sarcoidosis 
• Pb Toxicity (chronic) 
• Hypothyroidism 
 
 
INCREASED PRODUCTION: 
• Idiopathic 
• HGPRT deficiency (Lesch- Nyhan syndrome): It is an inherited X-
linked disorder. HGRPT is the key enzyme in the conversion of 
hypoxanthine to inosinate, where Phospho Ribosyl PyroPhosphate 
serves as the phosphate donor. The deficiency of this enzyme causes 
an accumulation of Phospho Ribosyl PyroPhosphate , which increases 
the production of purine and hence increased urate production. It is 
characterized by gout, uric acid nephrolithiasis, chorea, mental 
retardation and self-mutilation. 
• Partial deficiency of HGPRT (Kelley-Seegmiller syndrome): X-linked 
disorder with gouty arthritis, kidney stones, and mild cognitive 
deficits. 
• Increased PRPP synthetase function:  An uncommon disorder with 
symptoms similar to the previous condition 
• Increased nucleic acid turnover: seen in haemolytic anaemia of any 
cause and tumours such as Hodgkins- & Non Hodgkins Disease, 
leukaemia or myeloma 
• Tumour lysis syndrome: This is caused by rapid cell lysis of chemo 
sensitive tumour cells on starting therapy. It is one of the oncological 
emergencies. 
• Glycogenoses III, V, and VII 
 
COMBINED CAUSES 
• Alcohol (24) 
• Strenuous exercise with dehydration: Exercise may lead to increased 
cell destruction and decreased excretion due to mild volume 
depletion. 
• Aldolase B deficiency 
• Glucose-6-phosphatase deficiency (von Gierke disease) 
 
HYPERURICEMIA AND GOUT 
Hyperuricemia is the biochemical precursor of gout. Gout is an 
inflammatory response to monosodium urate monohydrate (MSUM) crystal 
deposition in the joints due to alteration in body urate milieu.  
 
New findings have revealed that urate crystals can engage an 
intracellular pattern recognition receptor, the macromolecular NALP3 
(cryopyrin) inflammasome complex which can result in interleukin 1 (IL-1) 
beta production (25). This causes inflammation. Inhibition of this pathway 
may be a target for hyperuricemia-induced crystal arthritis. 
 
 
 
 
 
Molecular basis of the inflammatory response 
Microcrystal shedding 
↓ 
Pro inflammatory coating (IgG, complements) 
↓ 
Interaction with tissue macrophages, fibroblasts, mast cells etc. 
↓ 
Activation of membrane signalling molecules (TLR, CD-14) 
↓ 
Release of cytokines (IL-1, TNF-α) & chemokines 
↓ 
Activation of endothelial cell adhesion molecules 
↓ 
Emigration, attraction and activation of neutrophils 
↓ 
Phagocytosis of crystals by neutrophils 
↓ 
Delayed neutrophil apoptosis by CSF, IL-1, IL-6 etc. 
 
It commonly occurs in men over 40 years of age. The incidence is 
raising over the last decade due to increased consumption of foods rich in 
purine, fructose containing and alcoholic beverages. Most frequent 
presentation is arthritis of first metatarsophalangeal joint (26). Articular gout 
may be acute, intercritical or chronic tophaceous gout. Diagnosis is confirmed 
by visualization of negatively birefringent MSU crystals in synovial fluid 
under polarized light microscopy or demonstration of MSU in tophi.  
 HYPERURICEMIA & KIDNEY DISEASE 
Three types of kidney diseases occur with hyperuricemia and gout: 
• Urolithiasis- Uric acid acting as nidus for calcium oxalate stone 
• Urate nephropathy- Late manifestation of severe hyperuricemia due to 
deposition of MSU crystals in the medullary interstitium and 
pyramids, leading to CRF and ESRD. 
• Uric acid nephropathy- Due to precipitation of uric acid in renal 
tubules or collecting ducts causing obstruction. It is usually seen in 
the setting of tumour lysis syndrome, in those with severe dehydration 
and acidosis. 
 
HYPERURICEMIA AND CARDIOVASCULAR DISEASE 
Multiple studies have confirmed the relationship between 
hyperuricemia, gout, CVD and metabolic syndrome (27). The NHANES III- 
USA has shown that serum urate more than 6 mg/dl is an independent risk 
factor for CAD and serum urate more than 7 mg/dl is an independent risk 
factor for stroke. 
 
Uric acid has long been considered a part of the dysmetabolic 
syndrome or a risk factor of other coronary disease markers like 
dyslipidemia, glucose intolerance, hypertension and renal disease. In 
patients with CCF, hyperuricemia correlates with increased mortality and 
indicates the needs for aggressive management of the problem. This has also 
been proved in angiographically confirmed CAHD who had hyperuricemia 
had a 5 fold risk of mortality. If there is an increase of serum uric acid by 1 
mg/dl, prospective studies show a 26% increase in mortality due to CAD. 
 
 
Richard J. Johnson et al 
(18, 19)
 reviewed the epidemiologic evidence and 
potential mechanisms for this association. The various studies that were 
included and showed a significant role of uric acid in CVD are: 
 
 
  
Some of the mechanisms postulated for the same in various groups are: 
 
 
They concluded that hyperuricemia had a potential role as a marker 
of CVD and its co morbidities especially Hypertension and Kidney disease. 
 
HYPERURICEMIA & METABOLIC SYNDROME 
A study conducted by Ford et al to analyse the role of uric acid in 
metabolic syndrome (29) concluded that in the paediatric age group, 
hyperuricemia was associated with the metabolic syndrome and its 
components and CRP. Several other studies have showed similar results. 
 
HYPERURICEMIA & HYPERTENSION 
Role of Uric Acid in Hypertension- The History 
In 1879, Frederick Akbar Mohamed noted in his paper on essential 
hypertension, that many of the hypertensive patients had a familial history 
of gout. He hypothesized that uric acid could be associated with 
development of essential hypertension (30). After ten years, Haig (31) 
identified that low-purine diets prevented hypertension and vascular 
disease. In 1909, Henri Huchard, a French academician observed renal 
arteriolosclerosis, a pathological hallmark of hypertension, in three groups: 
Those with gout, those with high fatty meat and those with lead poisoning. 
All three groups were found to have been associated with hyperuricemia. 
This association was observed in many studies and reported from 1950s 
but with no mechanistic explanation, not much importance was attached to 
it. Uric acid was no longer done as a part of routine laboratory 
investigations in the early 1980s. 
 
Animal Model for Hyperuricemia- The problem!! 
As with any other study, an animal model was required to test the 
hypothesis. The biggest problem in this, stems from the fact that while the 
enzyme urate oxidase is present in animals including most mammals, it is 
absent in humans and the great apes, which means that the normal serum 
uric acid levels in potential study models range between 0.5- to 1.5 mg/dl  
range ( this is about  3.6 to 7.1 mg/dl in humans),  and any additional uric 
acid that is administered in the diet or given intravenously gets rapidly 
metabolized to allantoin without any alteration of serum  levels. The 
solution for this would be an uricase knockout animal; but when they were 
bred, they developed urate nephropathy and died of kidney failure within 3 
months. Hence their use in studying chronic hyperuricemia was lost (10). 
In the end of 20th century, Johnson and colleagues (32, 33) were able to 
develop an animal model using an inhibitor of urate oxidase that produced 
a rat with sustained mild hyperuricemia. When 2% oxonate is added to the 
diet, these rats have their mean serum uric acid concentrations raised from 
0.6-1.5 g/dl to 1.8-3.1 mg/dl. Over the same 7 weeks, systolic BP increases 
by about 22 mmHg. This hypertension is prevented when allopurinol or 
benziodarone, a uricosuric agent are co administered, identifying uric acid 
as the cause of elevated BP. Histology of the tissue from rat’s kidney 
reveals narrowing of the lumina of the afferent arterioles and an expansion 
of the vascular smooth muscles (arteriolosclerosis) which is the 
pathognomonic of essential hypertension in humans. The development of 
arteriolosclerosis can be stopped using allopurinol to control 
hyperuricemia; hydrochlorhiazide on the other hand normalizes BP without 
lowering urate levels in blood and doesn’t prevent the same indicating that 
uric acid, is the causative stimulus, not hypertension in itself.  
 
The mechanisms by which hyperuricemia leads to hypertension have 
been studied using rat models. Direct staining of renal tissue for renin has 
shown that hyperuricemia causes staining in about 62% of juxtaglomerular 
apparatus, in comparison with less than 41% in the other study group. The 
histological study identified infiltration of renal parenchyma with 
macrophage, which means that increased uric acid levels in serum induces 
a pro inflammatory state in the kidney. Also, more than 48% reduction in 
total nitrate levels is noted during mild hyperuricemia. These results 
indicate that slight rise in uric acid levels causes activation of RAS, 
induces renal inflammation & CAUSES downregulation of production, all 
of which are probable pathways for uric acid–mediated hypertension. 
 
Some studies also have identified a probable reasoning for 
arteriolosclerosis induced by uric acid. Addition of uric acid to the growth 
medium induces Primary Human Vascular Smooth Muscle cells (HVSMC) 
to proliferate in a dose-dependent manner (36- 38). These cells express the 
urate-transport channel URAT1. The uric acid causes phosphorylation of 
kinases which in turn, activates transcription factors. The resultant increase 
in prostaglandins activates a) Platelet Derived Growth Factor leading to 
smooth muscle cell proliferation, and b) Monocyte Chemoattractant 
Protein-1that causes macrophage infiltration. This is depicted in the figure 
below. 
 
 
Role of uric acid in endothelial dysfunction 
It is well known that endothelial dysfunction predicts early onset of 
cardiovascular events. For assessment of endothelial function, Zoccali et al 
evaluated endothelial function (by intra-arterial infusion of acetylcholine 
(ACh) and compared with markers of cardiovascular risk such as C-reactive 
protein [CRP], insulin resistance, serum creatinine, and UA. They 
concluded that significant correlation exists between UA and endothelial 
dysfunction (39). 
 
Role of Uric Acid in Progressive Renal Injury: 
Uric acid–mediated arteriolopathy and interstitial inflammation 
provide us with a mechanism that explains progressive renal dysfunction. In 
a study done by Daniel et al, the influence of uric acid on various possible 
mechanisms of progressive renal injury was analysed (10). Two 
representative systems considered in this study were the remnant kidney 
model and cyclosporine nephropathy model in the rats. In the former, 
unilateral nephrectomy and ligation of the main branches renal arteries on 
the other side is done. The hyperuricemic remnant kidney rats (to whom 2% 
oxonic acid was added to diet) had higher BP, higher serum creatinine & 
greater proteinuria. An increase in glomerulosclerosis and interstitial 
fibrosis was noted compared to the normal remnant kidney model. Similar 
results were observed in the cyclosporine nephropathy model wherein 
addition of oxonic acid to cyclosporine treatment caused higher uric acid 
levels, with arteriolar hyalinosis, tubulointerstitial damage & macrophage 
infiltration. Also, allopurinol improves GFR in the latter model, as well as 
in human liver transplant patients receiving cyclosporine. 
 
URIC ACID AS A BIOMARKER OF HYPERTENSION 
A lot of studies have shown the association of hyperuricemia and 
hypertension. Some of these with the relative risk of hypertension as 
predicted by them are depicted in the table below: 
  
URIC ACID- A PREDICTOR OF FUTURE HYPERTENSION? 
Various studies done in the recent past have shown that serum uric 
acid may predict development of hypertension in future. The study by 
Khan et al. was one of the conclusive ones that showed that “an increased 
serum uric acid is an independent risk factor for hypertension (41). Klein et 
al showed that “there was a linear relationship between uric acid levels in 
serum and SBP irrespective of race (42). There were more than two reports 
published in the last decade of 20th century that indicated serum uric acid 
as an independent risk factor for hypertension (43-45), and five others 
published from 2000 to 2005 (46-50). The recent evaluation of a subset of the 
Framingham Heart Study found that “serum uric acid level was an 
independent predictor of hypertension and BP progression” (49). Krishnan 
et al studied the risk of developing hypertension in a follow-up study in 
men with normal blood pressure, without diabetes/glucose intolerance or 
metabolic syndrome with baseline hyperuricemia (serum uric acid 7.0 
mg/dL) and observed that men normal Blood pressure with asymptomatic 
hyperuricemia had more than 70% risk for developing hypertension 
compared with those who did not (50). Increase in serum uric acid by 1 
mg/dl was associated with more than 8% increase in the risk for developing 
hypertension 
 
URIC ACID IN PAEDIATRIC AGE GROUP: 
A significant association has been established between elevated 
serum uric acid and onset of essential hypertension in the adolescents. A 
Hypertension Study in Russia identified hyperuricemia (>8.0 mg/dl) in 
almost 10% of children with normal BP, nearly half of the children with 
borderline hypertension, and three- fourths of children with severe 
hypertension (51). A study in Hungary included all the children born in its 
capital city and followed them up for thirteen years and identified 
significant risk factors for the development of hypertension, which were: 
tachycardia, sexual maturity at a younger age, and increased uric acid 
levels (52). However, these studies didn’t categorize the study group by 
underlying cause of hypertension, and hence the relationship between 
levels of uric acid and hypertension might be skewed by ascertainment 
bias. In a small study, Gruskin et al compared essential hypertension of 
children in age group of 12- 18 years with healthy controls with normal BP 
(53). The hypertensive group had an elevated serum uric acid with a higher 
peripheral renin activity.  
 
Hyperuricemia- To treat or not to?? 
As presented, the results from various animal and human studies 
strongly implicate uric acid as one of the factor in the onset of essential 
hypertension in and also as a potential contributor to progressive renal 
injury (10). The animal models have also presented a mechanism wherein 
uric acid leads to various pathological changes in kidney such as afferent 
arteriolosclerosis, in hypertension. Arteriolosclerosis is irreversible and as 
shown in some studies, this hypertension becomes uric acid independent 
over a period of time. This possibly explains why xanthine oxidase 
inhibitors, such as allopurinol and uricosurics have not been found to be 
useful as antihypertensive agents. This also leads us to identify their 
potential use in the primary prevention of essential hypertension in selected 
populations. These data, however, are to be interpreted cautiously as we do 
not as yet have human clinical trial data to conclusively prove the use of 
uric acid–lowering agents as a potential antihypertensive agents, agents 
which prevent development of hypertension, or agents that attenuate 
progressive renal injury, like ACEI. Until then, the use of allopurinol or 
uricosuric agents is not warranted in asymptomatic hypertensives. With 
various clinical trials under way, the use of uric acid–lowering regimens 
may find a place in the treatment of hypertension. 
  
 
AIM OF THE STUDY 
 
1. To evaluate for the presence of Asymptomatic Hyperuricemia in 
Normotensive, Prehypertensive and Hypertensive Population 
2. To compare qualitatively and quantitatively, the serum Uric Acid 
levels in various Hypertensive classification groups. 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS & MATERIALS  
 
This study was conducted in the Government Kilpauk Medical 
College Hospital. Around 150 participants were included in the study. 
Informed consent was obtained from all individuals. Participants of the 
study were selected randomly from those attending outpatient clinics in the 
Department of Medicine, KMCH. Most of the individuals had either come 
for regular health visits or for problems like epigastric pain, upper 
respiratory tract infection, myalgia, headache etc. Since the study design 
has internal comparison among the hypertensive groups, no separate 
control group was selected. 
 
COLLABORATING DEPARTMENT: Department of Biochemistry 
INCLUSION CRITERIA: Normotensive, Pre- Hypertensive and 
Hypertensive patients (Known and Unknown) 
EXCLUSION CRITERIA:  
1. Known cases of Hyperuricemia/ Gout 
2. Known cases of  Leukaemia 
3. Patients with malignancies on chemotherapy/ RT 
4. Patients with Renal failure 
5. Patients with H/O Recent drug intake of ATT/Chronic Alcohol 
intake/ Diuretics 
 
METHODOLOGY: 
The subjects were evaluated for presence of Hypertension and were 
classified as per JNC VII Recommendation (Normotensive, Pre- 
Hypertensive, Hypertensive- stage I & II). Other details such as presence 
of hypertension and diabetes mellitus were noted. Anthropometric 
measurements were taken for them and BMI was calculated.  
 
Serum Uric Acid, along with fasting blood glucose and serum 
cholesterol was estimated in these patients. The uric acid was calculated 
from serum using uricase/ perioxidase method using an autoanalyser. The 
principle of the method is: 
 
Uric acid in the sample is subjected to coupled reactions described 
below, such that a coloured complex is formed. This involves reaction 
between uric acid and uricase which forms allantoin and peroxide. This 
peroxide reacts with 4- Aminoantipyrine in the presence of peroxidase to 
form Quinineimine, a coloured complex, which is measured using a 
spectrophotometry.   
 
All the data were collected on a proforma prepared for this study and 
was analysed. Hyperuricemia is taken as S. Uric Acid≥ 6.8mg/dl. 
 
RESULT & ANALYSIS 
 
Statistical analysis  
Mean values of all parameters in subgroups were calculated by 
independent sample-t-test. To compare the distributions of dichotomous 
data viz .gender, presence of hypertension or diabetes and hyperuricemia, 
Chi-square test was used. Association between Hypertension and 
hyperuricemia was assessed by logistic regression model. Potential 
confounders were adjusted for. Pearson correlations were applied to 
evaluate the correlation between Hypertension and age, sex, height, weight, 
BMI, blood sugar, cholesterol & uric acid levels. All statistical analyses 
were performed using the SPSS package .A p-value of less than 0.05 was 
considered to be statistically significant. The analysis is done for 
hypertensives and non hypertensives and further study is done among the 
various hypertensive groups. A total of 150 subjects in the age group of 30- 
60 yrs attending the outpatient department of our hospital were randomly 
selected and classified according to their BP into various hypertensive 
groups. The distribution of these subjects in these hypertensive groups is 
thus: 
 
 
 
Table 1: Distribution of Subjects According to Hypertensive Groups 
 
STAGE OF HT NO OF SUBJECTS 
NORMOTENSION 75 
PREHYPERTENSION 25 
STAGE I HYPERTENSION 33 
STAGE II HYPERTENSION 17 
 
DISTRIBUTION OF SUBJECTS ACCORDING TO HYPERTENSIVE GROUPS
NORMOTENSION
PREHYPERTENSION
STAGE I HYPERTENSION
STAGE II HYPERTENSION
 
Figure - 1 Distribution of Subjects According to Hypertensive Groups 
 
AGE GROUPS 
 
Table 2 : Distribution in Age Groups 
 
 
 
 
 
 
 
 
Figure – 2 : Age Distribution 
 
AGE GROUP(NO) Number of Patients Percentage 
30- 39(1) 39 26 
40-49(2) 52 34.7 
≥50(3) 59 39.3 
Table 3 : Mean Age 
 
 NUMBER MEAN AGE 
NORMOTENSIVE 75 43 
HYPERTENSIVE 75 49.31 
 
Chi square: p= 0.000 < 0.001. There exists a statistical significance between 
Hypertensive and normotensive subjects with respect to Age group 
distribution.  
 
 
Figure – 3 : Mean Age 
 
 
 
COMPARISON WITHIN HYPERTENSIVE GROUPS: 
Table 4 : Mean Age among Hypertensive Groups 
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Figure – 4 : Mean Age among Hypertensive Groups 
 
The average age of subjects was lesser in the normotensive group compared 
to any of the hypertensive subgroups. 
Hypertensive group Number Mean Age 
Normotension 75 43.00 
Pre Hypertension 25 50.40 
Stage I Hypertension 33 49.91 
Stage II Hypertension 17 46.53 
Total 150 46.15 
SEX GROUPS: 
A total of 71 males and 79 females participated in the study. 
 
 
Figure – 5 : Sex Distribution 
 
Table 5: Sex Distribution 
 
 MALES FEMALES 
NORMOTENSIVE 41 34 
HYPERTENSIVE 30 45 
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Figure – 6 : Percentage Distribution of Sex Groups  
 
 
Figure – 7 : Percentage Distribution among hypertensive Groups  
 
Chi square test: p=0.072 > 0.05 and hence no statistical significance exists 
between Hypertensive and normotensive with respect to sex distribution 
HEIGHT &WEIGHT: 
The mean height and weight of the subjects in various hypertensive 
groups is shown below: 
Table 6 : Mean Height and Weight 
  No of subjects Mean 
WEIGHT Hypertensive 75 66.00 
Non- Hypertensive 75 61.79 
HEIGHT Hypertensive 75 164.29 
Non- Hypertensive 75 163.25 
 
 
Figure – 8 : Mean Weight of Hypertensive Groups 
 
  
Figure – 9 : Mean Height of Hypertensive Groups 
 
Taking weight into consideration, using chi square test, p= 0.028 i.e. 
a statistical significance exists between hypertensive and normotensive 
population with respect to weight. However no statistical significance is 
seen between the groups and height. 
 
On doing post hoc analysis for multiple comparisons within the 
group, this significance for weight (p=0.01) existed only between the 
Normotension and Stage II Hypertension groups, and not among the 
other groups. 
Table 7 : Post Hoc Analysis of Weight 
 
(I) STAGE OF HT  
(J) STAGE OF 
HT 
Level of 
significance  
(p value) 
0 1 .270 
 2 .426 
 3 .001 
1 0 .270 
 2 .737 
 3 .036 
2 0 .426 
 1 .737 
 3 .012 
3 0 .001 
 1 .036 
 2 .012 
 
(0- NORMOTENSION; 1- PREHYPERTENSION;  
2- STAGE I HYPERTENSION; 3- STAGE II HYPERTENSION) 
BMI: 
Table 8 : Mean BMI 
 
 No of subjects Mean BMI 
HYPERTENSIVE 75 24.26 
NON HYPERTENSIVES 75 22.57 
 
 
Figure – 10 : Mean BMI 
 
With regards to BMI, P=0.000 i.e. There exists a statistical significance 
between hypertensive and normotensive patients with respect to BMI levels. 
In Hypertensive patients, the BMI level is elevated to 24.26 than  22.57 of 
Normotensive patients. 
The Mean BMI among the groups was: 
 
 
Figure – 11 : Mean BMI of Hypertensive Groups 
 
On post hoc multiple comparative analysis among the hypertensive 
groups, it is found that this statistical significance (p=0.000) exists between 
Stage II hypertension and the other groups and not among the others. In 
other words, there is a significant difference in BMI in patients with stage II 
Hypertension when compared to that in other hypertensive groups. 
 
 
 
Table 9 : Post Hoc Multiple Comparative Analysis of BMI 
 
STAGE OF HT STAGE OF HT 
SIGNIFICANCE 
(p value) 
0 
1 .494 
2 .087 
3 .000 
1 
0 .494 
2 .447 
3 .000 
2 
0 .087 
1 .447 
3 .000 
3 
0 .000 
1 .000 
2 .000 
 
(0-NORMOTENSION; 1- PREHYPERTENSION;  
2- STAGE I HYPERTENSION; 3- STAGE II HYPERTENSION) 
 
FASTING BLOOD SUGAR: 
Table 10 : Mean FBS 
 
 NO OF SUBJECTS MEAN FBS 
HYPERTENSIVE 75 134.60 
NORMOTENSIVE 75 117.97 
 
 
Figure – 12 : Mean FBS 
 
The mean fasting blood sugar value in the hypertensive population is 
134.6 mg/dl and is found to be statistically significant compared to the mean 
fasting blood sugar in normotensive study members (0.009). 
 
 
 
An analysis of FBS among the groups shows the following means: 
 
 
 
Figure – 13 : Mean FBS of Hypertensive Groups 
 
On post hoc multiple comparative analysis among the hypertensive 
groups, it is found that this statistical significance exists between Stage II 
hypertension and the other groups and not among the others.(P=0.000 
between stage II Hypertension and normotensives & Stage I Hypertension 
& P= 0.001 between Stage II Hypertension and pre hypertension groups). In 
other words, there is a significant difference in FBS in patients with stage II 
Hypertension when compared to that in other hypertensive groups. 
 
 
 
Table 11 : Post Hoc Multiple Comparative Analysis of FBS 
 
STAGE OF HT STAGE OF HT Significance (p value). 
0 
1 .223 
.602 
.000 
 
.223 
.514 
.001 
.602 
.514 
.000 
 
.000 
.001 
.000 
2 
3 
1 
0 
2 
3 
2 
0 
1 
3 
3 
0 
1 
2 
 
 
(0-NORMOTENSION; 1- PREHYPERTENSION;  
2- STAGE I HYPERTENSION; 3- STAGE II HYPERTENSION) 
 
SERUM CHOLESTEROL: 
 
Table 12  : Mean Cholesterol Levels 
 
 NO OF SUBJECTS MEAN CHOLESTEROL 
LEVEL 
HYPERTENSIVE 75 191.05 
NORMOTENSIVE 75 156.80 
 
 
 
Figure – 14 : Mean Cholesterol Levels 
 
The mean S. Cholesterol level in the hypertensives was 191.05 which 
is statistically significant (0.000) and higher compared to the levels in the 
normotensives. 
 
The Mean Serum Cholesterol levels in the various subgroups are: 
Table 13 : Mean Serum Cholesterol levels among Hypertensive Groups 
 
 
NO OF  
SUBJECTS 
MEAN CHOLESTEROL 
LEVELS 
NORMOTENSION 75 156.80 
PRE HYPERTENSION 25 179.84 
STAGE I 
HYPERTENSION 
33 172.61 
STAGE II 
HYPERTENSION 
17 243.35 
 
 
Figure – 15 : Mean Serum Cholesterol levels among Hypertensive 
Groups 
On post hoc multiple comparative analysis among the hypertensive 
groups, it is found that this statistical significance exists between Stage II 
hypertension and the other groups (P=0.000) and also between 
Normotensive and Pre hypertensive group (P=0.005). In other words, there 
is a significant difference in Serum cholesterol levels in patients with stage 
II Hypertension when compared to that in other hypertensive groups and 
between Normotensive and Prehypertensive subjects. 
Table 14 : post hoc multiple comparative analysis 
 
(I) STAGE OF HT (J) STAGE OF HT 
SIGNIFICANCE 
(P VALUE) 
0 
1 .005 
2 .034 
3 .000 
1 
0 .005 
2 .441 
3 .000 
2 
0 .034 
1 .441 
3 .000 
3 
0 .000 
1 .000 
2 .000 
 
(0-NORMOTENSION; 1- PREHYPERTENSION; 2- STAGE I 
HYPERTENSION; 3- STAGE II HYPERTENSION) 
SERUM URIC ACID: 
The primary aim of this study is to look at the levels of uric acid in 
various hypertensive groups and identify the level of hyperuricemia. 
 
Table 15  : Mean Serum Uric Acid  
 NO MEAN 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF MEAN 
HYPERTENSIVE 75 5.55 2.014 0.233 
NORMOTENSIVE 75 4.09 1.036 0.120 
 
 
Figure – 16 : Mean Serum Uric Acid 
With regards to Serum Uric Acid, P=0.000 i.e. There exists a 
statistical significance between hypertensive and normotensive patients with 
respect to BMI levels. In Hypertensive patients, the mean uric acid level is 
5.55 compared to 4.09 in Normotensive patients. 
 
Table 16  : Test of Significance  
 
 
 
Levene's Test for 
Equality of Variances 
t-test for Equality of 
Means 
Significance(p) 0.000 0.000 
 
Table 17  : Mean Serum Uric Acid among Hypertensive Groups 
 
 MEAN S. URIC ACID 
NORMOTENSION 4.09 
PRE HYPERTENSION 4.86 
STAGE I HYPERTENSION 5.08 
STAGE II HYPERTENSION 7.46 
 
 
 
Figure – 17 : Mean Serum Uric Acid among Hypertensive Groups 
 
On post hoc multiple comparative analyses among the hypertensive groups 
the following findings are present: 
a) Serum uric acid is elevated as the level of hypertension increases 
b) When compared to normotensive group, there is an elevation in uric 
acid levels in Stage I & II hypertensives which is statistically 
significant(p=0.001 & 0.000 respectively) 
c) The higher level of serum uric acid levels in the Stage II hypertension 
is statistically significant across all groups. 
 
Table 18 : Post Hoc Multiple Comparative Analyses of Uric Acid 
 
(I) STAGE OF HT (J) STAGE OF HT SIGNIFICANCE(P) 
0 
1 .022 
2 .001 
3 .000 
1 
0 .022 
2 .554 
3 .000 
2 
0 .001 
1 .554 
3 .000 
3 
0 .000 
1 .000 
2 .000 
 
 
(0-NORMOTENSION; 1- PREHYPERTENSION; 2- STAGE I 
HYPERTENSION; 3- STAGE II HYPERTENSION) 
 
 
 
 
HYPERURICEMIA: 
Hyperuricemia is taken as S. Uric acid > 6.8 mg/dl 
 
Table 19 : Frequency of Hyperuricemia 
 
Hyperuricemia Frequency Percentage 
Absent 128 85.3 
Present 22 14.7 
 
Out of the 150 subjects, 22 had hyperuricemia. 
 
 
Figure – 18 : Hyperuricemia among Subjects 
 
 
Table 20 : Distribution of Hyperuricemia among Hypertensive Groups 
 
 UA< 6.8 UA≥6.8 
 NUMBER PERCENT NUMBER PERCENT 
NORMOTENSION 74 57.8 1 4.5 
PRE 
HYPERTENSION 
23 18 2 9.1 
STAGE I 
HYPERTENSION 
27 21.1 6 27.3 
STAGE II 
HYPERTENSION 
4 3.1 13 59.1 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
NORMOTENSION PRE 
HYPERTENSION
STAGE I 
HYPERTENSION
STAGE II 
HYPERTENSION
UA ≥6.8
UA< 6.8
 
Figure – 19 : Hyperuricemia among Hypertensive Groups 
 
With regards to hyperuricemia, p=0.000 i.e. the correlation between 
hyperuricemia and hypertension is statistically significant 
CORRELATION OF HYPERURICEMIA WITH VARIOUS 
PARAMETERS WITH SBP & DBP: 
 
Table 21 : Mean SBP and DBP among Hyperuricemic Subjects 
 
  
NO OF 
SUBJECTS 
MEAN BP 
SBP 
HYPERURICEMIA 22 156.77 
NORMAL 128 122.87 
DBP 
HYPERURICEMIA 22 97.09 
NORMAL 128 81.91 
 
 
 
Figure – 20 : Mean SBP and DBP among Hyperuricemic Subjects 
With regards to BP values, p=0.000 i.e. the correlation between 
hyperuricemia and value of BP, both systolic & diastolic is statistically 
significant. The average SBP & DBP in the hyperuricemic subjects was 
156.77 & 97.09 mm Hg, values which almost correlates with Stage II 
Hypertension. 
  
WITH WEIGHT AND HEIGHT: 
Table 22 : Mean Weight and Height among Hyperuricemic Subjects 
  NO OF SUBJECTS Mean 
WEIGHT 
HYPERURICEMIA 22 70.91 
NORMAL 128 62.69 
HEIGHT 
HYPERURICEMIA 22 163.73 
NORMAL 128 163.78 
 
 
Figure – 21 : Average Weight among Hyperuricemic Subjects 
With regards to anthropometric measures: 
• For Weight measures, p=0.002 i.e. the correlation between 
hyperuricemia and weight is statistically significant. The average 
Weight in the hyperuricemic subjects was 70.79 kg compared to 
62.69 kg in the normal group. 
• For Height, the correlation is not statistically significant(p=0.9) 
 
WITH BMI: 
Table 23 : Mean BMI among Hyperuricemic Subjects 
 NO OF SUBJECTS MEAN BMI 
HYPERURICEMIA 22 26.25 
NORMAL 128 22.93 
 
 
Figure – 22 : Mean BMI among Hyperuricemic Subjects 
With regards to BMI, p=0.000 i.e. the correlation between hyperuricemia 
and BMI, is statistically significant. The average BMI in the hyperuricemic 
subjects was 26.25 kg, compared to 22.93 kg in normal subjects. 
 
INFERENCES FROM CORRELATIONAL STUDIES: 
• Level of hypertension increases with age 
• Greater the weight and BMI, higher is the Blood Pressure 
• Diabetics and those with high cholesterol levels have higher BP 
• There is a strong correlation between levels of uric acid and BP 
levels. The correlation is strongest for Stage II Hypertension 
• Asymptomatic hyperuricemia (UA≥6.8) correlates with advanced 
age, weight and BMI and higher SBP & DBP. 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In my study, 150 subjects attending the outpatient department of our 
hospital for minor ailments were screened. The study group included 71 
males and 79 females (47.3% & 52.3%) respectively. The age of the study 
group was between 30 & 60 yrs, with a distribution of 39.3%, 34.7% & 
26.0% when grouped for a decade. Among the 150 subjects, 75 were found 
to be normotensive while the rest had an abnormal BP. The distribution 
among the Prehypertensive, Stage I Hypertensive & Stage II Hypertensive 
groups was 17% 22% & 11% respectively.  
 
The mean age of the study group was 46.15 years. The mean age 
distribution among the normotensive, Prehypertensive, Stage I Hypertensive 
& Stage II Hypertensives was 43, 50.4, 49.9 & 46.53 years. Using ANOVA, 
the age distribution was found to be statistically significant meaning that age 
correlates with level of blood pressure with normotensive being younger 
than hypertensives.  However, the study also throws an interesting 
observation that among the hypertensive population, stage II Hypertensives 
seem to be younger than for lesser levels of hypertension, in the study 
group.  This is a dangerous finding and further studies are needed if this 
trend exists in the population at large or is just an incidental finding in this 
study. There was no correlation found between the sex groups and the 
development of hypertension. 
 
Analysis of the anthropometric measurements revealed that 
hypertensives tend to be obese compared to normotensives (66 & 61.29 kg 
respectively) and this was also statistically significant (p=0.028). Using post 
hoc analysis, this correlation was found to apply best on comparison of 
weight between the Normotension and Stage II Hypertension groups, and 
not among the other groups. However no correlation was made out between 
height and BP levels. On an expected note, the BMI also was found to be 
higher in hypertensives (p=0.00). The mean BMI level was 24.26 compared 
to 22.57 in the normotensive subjects. On post hoc analysis, this correlation 
was best appreciated between all the hypertensive groups and Stage II 
hypertensives i.e. these subjects were associated with very high BMI 
(27.26). 
 
Among the other biochemical parameters, both FBS and serum 
cholesterol levels were much higher in the hypertensive group (134.60 vs 
117.97 & 191.05 vs 156.80 respectively). In this correlation, multiple 
comparisons among the hypertensive groups were done. With regards to 
FBS, the difference in the value was significant between stage II 
hypertension (mean FBS- 168.3 mg/dl) and other groups. With regards to 
serum cholesterol, a similar relationship existed (S. Cholesterol in Stage II 
Hypertension=243.34 mg/dl). In addition, there was also significant 
difference between the cholesterol levels in normotensive and 
prehypertension groups. 
 
The major parameter in this study is S. Uric acid & Hyperuricemia. 
By levene’s test & independent t- test, the relation between uric acid levels 
and hypertension was found to be statistically significant (p=0.00) i.e. with 
increasing BP, the mean serum uric acid level also increases(5.55 mg/dl 
among hypertensives vs 4.09 mg/dl in  normotensive). The mean serum uric 
acid level among the hypertensive groups in increasing levels of BP is 4.09, 
4.86, 5.08 & 7.46(in mg/dl). On post hoc multiple comparative analyses 
among the hypertensive groups, there was an elevation in uric acid levels in 
Stage I & II hypertensives which was statistically significant(p=0.001 & 
0.000 respectively. The higher level of serum uric acid levels in the Stage II 
hypertension was statistically significant across all groups.  
 
Hyperuricemia was seen in 22 subjects out of the 150 (14.7%) and 
was distributed with increasing frequency with increasing BP, with almost 
60% of them in Stage II Hypertension. Using Pearson’s chi- square test, the 
relation between hyperuricemia and hypertension was found to be 
statistically significant (p=0.000). Hyperuricemia was associated with 
higher mean SBP (156 mm Hg) & DBP (97 mm Hg), values that almost 
near the levels of Stage II Hypertension. With regards to anthropometric 
measure, the correlation between hyperuricemia and weight was statistically 
significant (p=0.002). The average Weight in the hyperuricemic subjects 
was 70.79 kg compared to 62.69 kg in the normal group. For Height, the 
correlation was not statistically significant (p=0.9> 0.05). The correlation 
between hyperuricemia and BMI, was statistically significant (p=0.000). 
The average BMI in the hyperuricemic subjects was 26.25 kg, compared to 
22.93 kg in normal subjects. 
 
 These results are consistent with studies by Cannon et al whose 
studies had analysed the correlation between uric acid and level of 
hypertension (54). Their studies have shown that hyperuricemia was observed 
in 25% of hypertensive subjects who weren’t treated, half of those on 
treatment, and almost all of those with malignant hypertension. Another 
study by Bulpitt et al (55) reported that elevated levels of uric acid were 
observed in half of hypertensive subjects at the national level.  
 
The data from the First National Health and Nutrition Examination 
Survey (NHANES I) from NHANES I Epidemiologic Follow-up Study 
(NHEFS) were analysed in a landmark trial by Fang et al (56). Around 6000 
subjects were studied and the correlation between serum uric acid and 
cardiovascular risk factors were analysed. Our results were consistent with 
the findings in their study which showed a significant association between 
uric acid and factors like blood sugar, serum cholesterol and BMI. Their 
results are tabulated thus. 
 
 
 
CONCLUSION 
 
The findings in my study reinstate the analyses done in western world 
on the correlation between uric acid and hypertension. All hypertensive 
groups have elevated uric acid levels. The strongest correlation among the 
hypertensive groups is found in stage II Hypertension. It is also seen that as 
the stage of hypertension increases, the mean uric acid levels also increase. 
There is a sudden rise in the mean values from stage I to stage II. This 
suggests that there might be a significant role of uric acid in 
pathophysiology of complications of hypertension as it is well established 
that higher grades of hypertension are associated with greater degree of end 
organ damage. Asymptomatic hyperuricemia (S. Uric acid≥ 6.8 mg/dl) is 
significantly associated with all factors making up the components of 
metabolic syndrome, consistent with similar studies done in this regard. The 
correlation between serum uric acid levels and hypertension is an important 
paradigm in the identification of multiple factors involved in the 
pathophysiology of hypertension. The need for this comes from the fact that 
hypertension is a major morbidity and mortality factor which is becoming 
increasingly prevalent in our country. As further studies are in progress, 
there may come a time when drugs lowering uric acid may play a role in 
primary prevention of hypertension or secondary prevention of 
complications. 
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PROFORMA 
 
NAME: 
AGE:       SEX: 
ADDRESS: 
OP NO: 
PRESENTING COMPLAINTS: 
PAST HISTORY: 
DRUG HISTORY: 
LIFE STYLE HISTORY: 
 
EXAMINATION: 
GENERAL: 
Built:  Pallor: Pedal Oedema: Facial Puffiness: 
VITALS: 
 
BP MEASUREMENTS: 
I:   II:   BP (Final): 
Stage Of Hypertension (As Per JNC VII): 
Pulse Rate: 
Weight:  Height:  BMI:   
SYSTEMIC EXAMINATION: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
MUSCULOSKELETAL: 
 
INVESTIGATIONS: 
RANDOM BLOOD SUGAR: 
LIPID PROFILE: 
S. URIC ACID: 
Hyperuricemia:  Y or N 
 
ANALYSIS: 
 
 
 
 
 
 
 
MASTERCHART 
 
Name Age Sex 
Duration 
of SHT 
Duration 
of DM 
SBP 
1 
DBP 
1 
SBP 
2 
DBP 
2 
SBP 
Final 
DBP 
Final 
Stage of 
SHT 
Weight 
in Kg 
Height 
in cm 
BMI 
S.uric 
acid 
Hyperuricemia FBS S.cholesterol 
DEVI 30 F 
  
100 72 100 72 100 72 NORMO 54 168 19 2.3 N 90 130 
UMA MAHESWARI 30 F 
  
110 80 110 80 110 80 NORMO 48 155 20 2.4 N 70 105 
SELVI 33 F 
  
100 70 100 70 100 70 NORMO 54 157 22 2.8 N 134 176 
BANU 33 F 
  
110 70 110 70 110 70 NORMO 71 165 26 3.4 N 142 167 
KALA 33 F 
  
120 80 120 80 120 80 NORMO 48 155 20 4 N 96 134 
RENUKA 34 F 
  
100 70 100 70 100 70 NORMO 73 178 23 2 N 80 187 
SANTHAKUMARI 34 F 
  
100 78 100 70 100 74 NORMO 78 168 28 4.3 N 120 234 
KAMARUNISHA 36 F 
  
120 80 120 80 120 80 NORMO 43 115 19 4.9 N 150 140 
TAMIL ILAKIYA 36 F 
  
110 70 110 70 110 70 NORMO 62 163 23 2.5 N 80 179 
AMMU 36 F 
  
110 80 110 80 110 80 NORMO 63 165 23 2.5 N 89 142 
INDRA 37 F 
  
120 70 120 70 120 70 NORMO 57 155 24 4.1 N 100 134 
RAMAYEE 37 F 
  
120 80 120 80 120 80 NORMO 42 156 20 4.2 N 110 156 
JAYASREE 38 F 
  
96 66 100 66 98 66 NORMO 64 165 20 2.7 N 115 140 
SHALU 38 F 
 
NEW 110 80 110 80 110 70 NORMO 83 175 27 5.1 N 155 219 
MUNIAMMAL 39 F 
  
110 80 110 80 110 80 NORMO 51 160 20 4.9 N 109 110 
RAMYA 39 F 
  
110 70 110 70 110 70 NORMO 68 172 23 4.6 N 230 180 
DHANALAKSHMI 40 F 
  
110 70 110 70 110 70 NORMO 64 165 20 6.9 Y 120 234 
JACQUELIN 40 F 
  
110 80 110 80 110 80 NORMO 66 170 23 3.6 N 104 155 
HAMSA 42 F 
  
100 78 100 70 100 74 NORMO 48 155 20 4.8 N 120 156 
ANJALAI 43 F 
  
110 80 110 80 110 80 NORMO 42 156 20 5.8 N 80 118 
USHA 45 F 
  
100 70 110 70 100 70 NORMO 43 115 19 3 N 80 112 
ANANTHANAYAGI 45 F 
  
110 80 110 80 110 80 NORMO 64 165 20 4.7 N 148 168 
RADHA 45 F 
  
120 88 120 80 120 84 NORMO 83 175 27 5 N 123 165 
Name Age Sex 
Duration 
of SHT 
Duration 
of DM 
SBP 
1 
DBP 
1 
SBP 
2 
DBP 
2 
SBP 
Final 
DBP 
Final 
Stage of 
SHT 
Weight 
in Kg 
Height 
in cm 
BMI 
S.uric 
acid 
Hyperuricemia FBS S.cholesterol 
CHINNAPONNU 45 F 
  
110 80 110 80 110 80 NORMO 62 163 23 3 N 100 132 
THULUKANAM 46 F 
  
110 70 110 70 110 70 NORMO 78 168 28 3.5 N 110 160 
RADHIKA 46 F 
  
110 80 110 80 110 80 NORMO 48 155 20 4 N 90 110 
JAYALAKSHMI 47 F 
  
110 80 110 80 110 80 NORMO 48 155 20 3.1 N 115 140 
THAVASELVI 50 F 
 
15 120 80 120 80 120 80 NORMO 55 155 23 2.5 N 155 146 
BADHUR NISHA 50 F 
  
110 80 110 80 110 80 NORMO 60 157 25 3.3 N 90 130 
MANMAYA 53 F 
  
110 80 110 80 110 80 NORMO 61 175 20 5 N 89 177 
DHANALAKSHMI 53 F 
 
NEW 110 80 110 80 110 80 NORMO 42 156 20 2.5 N 176 156 
SORAJA 54 F 
 
15 110 80 110 80 110 80 NORMO 51 160 20 3.6 N 176 155 
SAVITHRI 58 F 
  
110 80 110 80 110 80 NORMO 64 165 20 3.1 N 100 150 
JAYALAKSHMI 60 F 
  
110 80 110 80 110 80 NORMO 54 150 24 4.7 N 122 268 
HARISH 30 M 
  
120 80 120 80 120 80 NORMO 55 155 23 4.4 N 78 154 
TIRUMALAI 30 M 
  
110 70 110 70 110 70 NORMO 68 172 23 4.6 N 102 155 
SUBBURAYAN 30 M 
  
100 70 100 70 100 70 NORMO 78 168 28 4.2 N 105 150 
RAMESH 30 M 
  
110 80 110 80 110 80 NORMO 68 172 22 4 N 90 120 
YASEEN 30 M 
  
96 60 100 60 98 60 NORMO 48 155 20 4.3 N 88 120 
SAKTIVAL 31 M 
  
110 70 110 70 110 70 NORMO 55 163 21 3.2 N 88 132 
DHANANJAYAN 32 M 
  
120 80 120 80 120 80 NORMO 68 172 22 4.6 N 98 175 
RAMAKRISHNAN 32 M 
  
100 80 100 80 100 80 NORMO 64 165 20 3.8 N 86 100 
PRAKASH 32 M 
  
100 70 100 70 100 70 NORMO 71 165 26 4.2 N 90 150 
NAVEEN 33 M 
  
110 80 110 80 110 80 NORMO 67 168 24 4.1 N 107 140 
SIVA 36 M 
  
120 80 120 80 120 80 NORMO 55 163 21 4.5 N 100 146 
GOVINDAN 38 M 
  
110 80 110 74 110 77 NORMO 64 165 20 5.7 N 90 110 
KUMAR 38 M 
  
110 70 110 70 110 70 NORMO 48 155 20 5.5 N 144 178 
KUMAR 39 M 
  
120 80 124 80 122 80 NORMO 64 165 20 3.7 N 88 150 
Name Age Sex 
Duration 
of SHT 
Duration 
of DM 
SBP 
1 
DBP 
1 
SBP 
2 
DBP 
2 
SBP 
Final 
DBP 
Final 
Stage of 
SHT 
Weight 
in Kg 
Height 
in cm 
BMI 
S.uric 
acid 
Hyperuricemia FBS S.cholesterol 
HARRIS 39 M 
  
100 66 100 68 100 67 NORMO 68 172 22 3.8 N 100 150 
RAVIKUMAR 40 M 
  
120 80 120 80 120 80 NORMO 61 160 24 6 N 154 168 
RAVIKUMAR 40 M 
  
120 80 120 80 120 80 NORMO 42 156 20 4.4 N 80 160 
MAYILVAHANAN 41 M NEW 
 
146 94 146 94 146 94 NORMO 81 168 29 4.7 N 122 170 
RAVI 42 M 
  
120 70 120 70 120 70 NORMO 55 163 21 4.8 N 110 160 
SIVAKUMAR 42 M 
  
110 80 110 80 110 80 NORMO 66 178 21 3.1 N 98 143 
ISMAIL 42 M 
  
120 80 120 80 120 80 NORMO 55 163 21 3.6 N 120 234 
SHANKAR 45 M 
  
110 70 110 70 110 70 NORMO 68 172 23 3.8 N 90 130 
MUNIUSAMY 46 M 
  
110 80 110 80 110 80 NORMO 55 163 21 5 N 110 123 
SRINIVASAN 47 M 
  
120 80 120 80 120 80 NORMO 68 172 22 6.5 N 120 180 
BABU 48 M 
  
110 80 110 80 110 80 NORMO 55 155 23 4.4 N 180 150 
JAYASEELAN 48 M 
  
110 80 110 80 110 80 NORMO 73 178 23 3.5 N 123 165 
ISMAIL 48 M 
  
100 80 100 80 100 80 NORMO 83 175 27 3.8 N 130 150 
SATISH 49 M 
  
120 80 120 80 120 80 NORMO 72 160 28 4.7 N 130 179 
CHANDRAMOHAN 49 M 
 
2 120 80 120 80 120 80 NORMO 81 168 29 4.5 N 180 187 
THOMAS 50 M 
  
100 70 100 70 100 70 NORMO 83 175 27 3.7 N 148 168 
ANBUSELVAM 50 M 
 
4 110 80 110 80 110 80 NORMO 51 160 20 4.3 N 155 210 
DEVAN 54 M 
 
15 110 80 110 80 110 80 NORMO 59 168 21 4.8 N 190 180 
KAMAL 55 M 
  
110 80 110 80 110 80 NORMO 63 165 23 5.2 N 144 178 
GANDEEBAN 55 M 
  
120 70 120 70 120 70 NORMO 68 172 23 3.1 N 150 140 
SUBRAMANIAM 55 M 
  
110 80 110 80 110 80 NORMO 78 168 28 3.8 N 78 123 
ANNAMALAI 56 M 
  
120 80 120 80 120 80 NORMO 66 170 23 2.5 N 130 179 
LAKSHMANAN 58 M 
  
120 80 120 80 120 80 NORMO 81 168 29 4.1 N 148 168 
SUBRAMANI 60 M 
  
110 70 110 70 110 70 NORMO 66 170 23 6.6 N 98 160 
SANTHANAM 60 M 
 
5 120 80 120 80 120 80 NORMO 55 163 21 3.7 N 230 180 
Name Age Sex 
Duration 
of SHT 
Duration 
of DM 
SBP 
1 
DBP 
1 
SBP 
2 
DBP 
2 
SBP 
Final 
DBP 
Final 
Stage of 
SHT 
Weight 
in Kg 
Height 
in cm 
BMI 
S.uric 
acid 
Hyperuricemia FBS S.cholesterol 
MANIKANNAYYA 60 M 
  
120 88 120 80 120 84 NORMO 68 172 22 4.3 N 110 160 
AYYAVU 60 M 
  
120 80 120 80 120 80 NORMO 48 155 20 4.7 N 98 120 
BAVANI 33 F 
  
130 90 130 90 130 90 PRE 66 178 21 4.2 N 115 140 
LAKSHMI BAI 40 F 
  
130 90 130 90 130 90 PRE 60 160 23 4.2 N 133 177 
DURGA DEVI 41 F 
  
130 80 130 90 130 85 PRE 68 172 23 6.2 N 121 188 
USHA 45 F 
 
5 130 80 130 80 130 80 PRE 48 154 20 3 N 176 188 
ELIZABETH 47 F 
  
130 80 130 80 130 80 PRE 62 158 25 1.9 N 90 160 
KASTHURI 57 F 
  
136 80 136 80 136 80 PRE 60 161 24 4.9 N 100 150 
PARVATHY 60 F 
  
130 70 130 80 130 75 PRE 62 163 23 3.8 N 110 130 
SUSEELA 60 F 
  
132 86 132 86 132 86 PRE 48 155 20 3.1 N 80 122 
RADHAMMAL 60 F 
  
130 80 130 80 130 80 PRE 83 175 27 3 N 77 156 
VALLIAMMAL 60 F 
 
8 130 80 130 80 130 80 PRE 64 165 20 4.3 N 180 245 
SATISH 32 M 
  
130 80 130 80 130 90 PRE 61 175 20 5 N 145 210 
MURUGAN 33 M 
  
136 86 132 80 134 83 PRE 83 175 27 6 N 170 220 
SATYARAJ 42 M 
  
130 90 130 90 130 90 PRE 64 168 23 4.2 N 90 120 
RAVI 46 M 
  
130 90 130 90 130 90 PRE 51 160 20 6.5 N 122 180 
GANESH 48 M 
  
130 80 130 80 130 80 PRE 66 170 23 3.9 N 150 140 
SEKAR 50 M 
  
130 90 130 90 130 90 PRE 55 163 21 8 Y 190 255 
SAHAYA RAJ 50 M 
  
130 80 130 80 130 80 PRE 72 160 28 5.9 N 112 132 
KUBERAN 50 M 
  
130 80 130 80 130 80 PRE 83 175 27 4.9 N 130 170 
MANI 53 M 
 
5 130 90 130 90 130 90 PRE 66 170 23 4.6 N 180 198 
PRAKASH 56 M 
  
130 90 130 90 130 90 PRE 70 175 23 6.1 N 85 198 
PALANI 57 M 
  
130 80 130 80 130 80 PRE 55 163 21 5.8 N 110 280 
PAZHANISAMY 60 M 
  
130 80 130 80 130 80 PRE 83 175 27 5 N 120 156 
RATHINAM 60 M 
  
130 90 130 90 130 90 PRE 64 165 20 6.8 Y 132 221 
Name Age Sex 
Duration 
of SHT 
Duration 
of DM 
SBP 
1 
DBP 
1 
SBP 
2 
DBP 
2 
SBP 
Final 
DBP 
Final 
Stage of 
SHT 
Weight 
in Kg 
Height 
in cm 
BMI 
S.uric 
acid 
Hyperuricemia FBS S.cholesterol 
NAVIN 60 M 
  
130 80 130 80 130 80 PRE 63 165 23 5 N 108 160 
RAJAMANI 60 M 
 
5 130 90 130 90 130 90 PRE 61 160 24 5.2 N 180 200 
KAUSALYA 35 F NEW 12 140 90 140 90 140 90 I 72 160 28 6.6 N 166 198 
MARY 40 F 2 
 
150 90 150 90 150 90 I 54 150 24 7.2 Y 123 156 
MABHUNISHA 40 F 4 
 
140 100 140 100 140 100 I 51 153 22 3.4 N 80 122 
IRUDAYARANI 41 F NEW 
 
140 100 140 90 140 95 I 54 150 24 4.2 N 110 160 
VASUKI 43 F 1 
 
140 90 140 90 140 90 I 84 168 30 5.7 N 133 188 
JAYALAKSHMI 45 F 2 
 
140 96 140 96 140 96 I 60 157 25 8 Y 142 244 
LOGANAYAGI 45 F 1 3 140 90 140 100 140 95 I 81 168 29 4.8 N 100 143 
AARTHI 45 F NEW NEW 150 90 150 90 150 90 I 62 159 24 6 N 205 190 
KALA 46 F 0 
 
140 80 140 80 140 80 I 63 165 23 6.6 N 132 180 
BEAULA 48 F 1 
 
140 100 140 90 140 95 I 83 175 27 6.1 N 120 178 
SUJEETHA 48 F 2 
 
140 90 140 90 140 90 I 48 155 20 5 N 99 149 
SHANMUGAVALLI 50 F NEW 
 
130 90 130 90 130 90 I 55 163 21 3.3 N 98 165 
FATHIMA 51 F 10 
 
140 90 140 90 140 90 I 66 170 23 6.8 Y 133 187 
ELLAMMA 55 F 
  
140 94 136 90 138 92 I 60 157 25 8.8 Y 120 256 
KARUPAYEE 55 F 5 5 140 90 140 90 140 90 I 83 175 27 3 N 100 154 
KANTHA 55 F 3 
 
140 100 140 90 140 95 I 52 159 20 4.1 N 110 165 
DHANALAKSHMI 55 F 2 
 
140 90 140 90 140 90 I 51 157 20 1.9 N 109 151 
RAJBHAI 60 F 
 
2 142 80 140 80 141 80 I 72 160 28 8.8 Y 221 240 
SUBBAMMA 60 F 4 
 
150 90 150 90 150 90 I 64 165 20 4.3 N 110 165 
RUKMANI 60 F 2 
 
140 80 140 80 140 80 I 68 172 22 4.2 N 88 143 
RANI 60 F 5 
 
140 90 140 90 140 90 I 60 168 21 4.2 N 98 159 
KASTHURI 60 F 5 10 130 90 130 90 130 90 I 50 156 20 2.9 N 108 154 
BABU 30 M 
  
140 90 140 90 140 90 I 63 165 23 4.3 N 123 165 
VADIVELU 43 M NEW 
 
150 96 150 90 150 93 I 42 156 20 2.8 N 100 132 
SHANMUGAM 45 M 5 
 
150 100 150 100 160 100 I 95 172 32 4.3 N 155 210 
SRINIVASAN 46 M 5 
 
140 90 140 90 140 90 I 54 168 19 4.9 N 130 179 
KANNIAPPAN 48 M 
  
130 90 130 90 130 90 I 54 164 20 3.7 N 98 167 
MOORTHY 54 M 
  
150 100 154 100 152 100 I 67 168 24 5.1 N 116 158 
VENKATESH 54 M NEW 
 
140 90 140 90 140 90 I 64 163 24 4.5 N 144 188 
RADHAKRISHNAN 55 M NEW 
 
146 90 146 90 146 90 I 63 165 23 6.1 N 88 140 
BHASKAR 57 M 
  
146 90 140 90 143 90 I 70 175 23 4.4 N 120 156 
PATTBIRAMAN 58 M 1 
 
140 90 140 90 140 90 I 54 157 22 4.9 N 125 174 
THANGAN 60 M 1 
 
150 90 150 90 150 90 I 83 175 27 6.9 Y 120 180 
INDRA 37 F 5 5 160 100 160 100 160 100 II 74 162 28 8.8 Y 210 276 
CHOKKAMMA 40 F 4 
 
150 100 150 100 150 100 II 68 172 23 7.3 Y 143 203 
RAMYA 44 F 5 8 180 100 180 100 180 100 II 70 158 28 8 Y 210 255 
LILLY 48 F NEW 
 
160 100 160 100 160 100 II 56 157 22 2.6 N 124 144 
DEVI 48 F 10 8 200 110 200 120 200 115 II 60 149 28 9.8 Y 258 243 
DEVI 49 F NEW 
 
168 100 162 100 165 100 II 78 168 28 8.7 Y 110 275 
KAVITA 50 F 
  
160 100 160 100 160 100 II 81 168 29 8 Y 110 280 
JAMUNA 50 F NEW 
 
170 90 170 100 170 95 II 78 168 28 7.8 Y 123 185 
DHANAM 50 F 5 
 
150 110 150 110 150 110 II 70 163 28 6.6 N 140 200 
GAYATRI 50 F 8 8 190 110 190 110 190 110 II 70 152 31 10 Y 277 287 
AMMU 53 F 
 
NEW 160 100 160 96 160 98 II 83 175 27 7.2 Y 132 266 
KUPPU 54 F 3 
 
160 100 160 100 160 100 II 70 158 28 3 N 100 160 
CHANDRA 55 F 2 
 
170 100 170 100 170 100 II 60 160 23.5 7.2 Y 160 275 
NAGARAJ 30 M NEW NEW 180 120 170 110 175 115 II 95 172 32 10.6 Y 208 256 
NAZEEMUDIN 37 M NEW NEW 170 100 170 100 170 100 II 52 154 21 4.7 N 180 288 
CHERAN 42 M NEW 
 
170 110 170 110 170 110 II 84 168 30 9 Y 146 268 
RAJATRATNAM 54 M 2 5 170 110 170 100 170 105 II 81 168 29 7.5 Y 234 276 
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